Skyhawk Therapeutics and Merck KGaA announced a collaboration aiming to develop RNA splicing modulators targeting neurological diseases, with potential payments up to $2 billion. Skyhawk will apply its SkySTAR platform for small molecule discovery, while Merck may advance candidates into clinical development. The partnership targets diseases considered challenging for traditional approaches and underscores the growing interest in RNA modulation technologies within neurology.